Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model

Experimental Oncology

Volumn 29, Issue 4, 2007, Pages 267-271

  Reznikov, A G ^a   Chaykovskaya, L V ^a   Polyakova, L I ^a   Kornelyuk, A I ^b  

^a STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^b INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

Author keywords

EMAP II; Endothelial monocyte activating polypeptide II; Prostate cancer; Xenografts

Indexed keywords

ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; ENTEROPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ESCHERICHIA COLI; HISTOPATHOLOGY; LOW DRUG DOSE; MOUSE; NONHUMAN; PROSTATE ADENOCARCINOMA; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 39049168042     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Barnett G, Jakobsen AM, Tas M, et al. Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress. Cancer Res 2000; 60: 2850-7.
2. Berger AC, Alexander HR, Wu PC, et al. Tumor necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumor-derived cytokine endothelial monocyte-activating polypeptide II (EMAP-II). Cytokine 2000; 12: 992-1000.
3. Berger AC, Tang G, Alexander HR, Libutti SK. Endothelial monocyte-activating polypeptide II, a tumor-derived cytokine that plays an important role in inflammation, apoptosis, and angiogenesis. J Immunother 2000; 23: 519-27.
4. Bogden AE, Cobb WR, Lepage DJ, et al. Chemotherapy responsiveness of human tumors as first transplant generation in the normal mouse: six-day subrenal capsule assay. Cancer 1981; 48: 10-20.
5. Dubrovsky AL, Brown Jn, Kornelyuk AI, et al. Bacterial expression of full-length and truncated forms cytokine EMAP-2 cytokine-like domain of mammalian tyrosyl-tRNA syntetase. Biopolymers and Cell(Kiev) 2000, 16: 229-35.
6. Gnant MFX, Berger AC, Huang J, et al. Sensitization of tumor necrosis factor-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res 1999; 59: 4668-74.
7. Ivakhno SS, Kornelyuk AI. Cytokine-like activities of some aminoacyl-tRNA synthetases and auxiliary p43 cofactor of aminoacylation reaction and their role in oncogenesis. Exp Oncol 2004; 26: 250-5.
8. Kao J, Houck K, Fan Y, et al. Characterization of a novel tumor-derived cytokine endothelialmonocyte-activating polypeptide II. J Biol Chem 1994; 269: 25106-19.
9. Kao J, Ryan J, Brett G, et al. Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. J Biol Chem 1992; 267: 20239-47.
10. Kayton ML, Libutti SK. Endothelialmonocyte-activating polypeptide II (EMAP II) enchances the effect of TNA on tumor-associated vasculature. Curr Opin Invest Drugs 2001; 2: 136-8.
11. Keezer SM, Ivie SE, Krutzsch HC, et al. Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. Cancer Res 2003; 63: 6405-12.
12. Kornelyuk AI, Tas M, Dubrovsky A, Murray JC. Cytokine activity of the non-catalytic EMAP 2-like domain of mammalian tyrosyl-tRNA synthetase. Biopolymers and Cell (Kiev) 1999, 15: 168-72.
13. Lans TE, van Horssen R., Eggermont AM, Hagen TL. Involvement of endothelial-monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy. Anticancer Res 2004; 24: 2243-8.
14. Lee YS, Han JM, Kang T, et al. Antitumor activity of the novel human cytokine AIMP1 in an vivo tumor model. Mol Cells 2006; 21: 213-7.
15. Marvin M, Libutti S, Kayton M, et al. A novel tumor-derived mediator that sensitizes cytokine-resistant tumors to tumor necrosis factor. J Surg Res 1996, 63: 248-55.
16. Schwarz MA, Kandel J, Brett J, et al. Endothelial-monocyte activating polypeptide II. A novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med 1999; 190: 341-54.
17. Schwarz MA, Zheng H, Liu J, et al. Endothelial-monocyte activating polypeptide II alters fibronectin based endothelial cell adhesion and matrix assembly via alpha5 beta integrin. Exp Cell Res 2005; 311: 229-39.
18. Schwarz RE, Schwarz MA. In vivo therapy of local tumor progression by targeting vascular endhothelium with EMAP II. J Surg Res 2004; 120: 64-72.
19. van Horssen R, Eggermont AM, ten Hagen TL. Endothelial monocyte-activating polypeptide II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev 2006; 17: 339-48.
20. van Horssen R, Rens JA, Schipper D, et al. EMAP-II facilitates TNF-R1 apoptotic signaling in endothelial cells and induces TRADD mobilization. Apoptosis 2006; 11: 2137-45.
21. van Horssen R, ten Hagen TL, Eggermont AM. TNF in cancer treatment: Molecular insights, antitumor effects and clinical utility. The Oncologist 2006, 11: 397-408.
22. Vozianov A, Reznikov A, Klimenko I. Androgen deprivation strategy in prostate cancer. Kyiv: Naukova Dumka, 2001. 240 p.
23. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science. 1999; 284: 147-51.
24. Wu PC, Alexander HR, Huang J, et al. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAP II). Cancer Res 1999; 59: 205-12.
25. Zhang FR, Scwarz MA. Pro-EMAP II is not primarily cleaved by caspase-3 and -7. Am J Physiol Lung Cell Mol Physiol 2002; 282: L1239-44.